$NTRA

Chapman Steven Leonard sold $279K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,300 shares of Natera, Inc. (NTRA) at $214.83 ($0.28M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure may influence short-term sentiment, but 10b5-1 structure generally limits inference about near-term business outlook.

02

Market read

Traders may monitor whether additional insider sales occur, but this single 10b5-1 sale is unlikely to drive a durable repricing alone.

03

What to watch

The sale size is modest relative to typical large-cap float; without additional context (e.g., total planned volume, prior sales), signal is weak.

Relevance 6/10Novelty 4/10Timing: insider sale disclosed after-hours/next session following the 2026-06-04 trade date

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/president under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $279,279 of NTRA shares via an open-market transaction disclosed on Form 4.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is an insider transaction (not earnings/M&A/regulatory). It explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider liquidity rather than a sector catalyst.

None.

None.

Counterpoint

If the market treats 10b5-1 sales as still informative, the stock could see a brief dip as traders front-run potential future selling.

Key entities

  • Natera, Inc.

    Subject of the insider transaction disclosure; CEO/president sold shares on 2026-06-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.